Sanara MedTech Inc. (NASDAQ:SMTI) Q1 2024 Earnings Conference Call May 14, 2024 9:00 AM ET

Company Participants

Callon Nichols - Director of IR
Ron Nixon - Executive Chairman
Mike McNeil - CFO
Seth Yon - President, Commercial

Conference Call Participants

Ian Cassel - IFCM

Operator

Greetings, welcome to the Sanara MedTech Inc. First Quarter Results and Business Update Conference Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]

Please note this conference is being recorded. I will now turn the conference over to your host, Callon Nichols, Director of Investor Relations at Sanara MedTech. Callon, you may begin.

Callon Nichols

Thank you and good morning, everyone. I'd like to welcome you to the Sanara MedTech's earnings conference call for the quarter ended March 31, 2024. We issued our earnings release yesterday morning, and I would like to highlight that we have posted today's deck on the investor relations page of our website. This supplemental deck, as well as a copy of the earnings release and the Form 10-Q for the quarter ended March 31, 2024 are also available on this page.

We will reference this information in our remarks today. With us today are Ron Nixon, our Executive Chairman and CEO, Mike McNeil, our Chief Financial Officer, and Seth Yon, our President, Commercial. Please note that certain statements in this conference call and our press release and in our supplemental deck include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information about the risk and uncertainties involving forward-looking statements and factors that could cause actual results to differ materially from those projected or implied by forward-looking statements, please see the risk factor set forth in our most recent Annual Report on Form 10-K, as supplemented by the risk factors in our most recent quarterly report on Form 10-Q.

Also, this conference call, our earnings release, and supplemental deck reference certain non-GAAP measures. In that regard, I direct you to the reconciliation of these measures and the earnings materials that are available on our website.

Now I'd like to turn the call over to Ron.

Ron Nixon

Thank you, Callon, and good morning, everyone. As we mentioned in our press release yesterday, our former CEO, Zach Fleming, resigned on Friday. We're in the process of finalizing a separation agreement with Zach and I've been appointed CEO by the company's Board of Directors. As a result of Zach's departure, the company will no longer be presenting the proposal for the election of a ninth director on our Board of Directors at the annual meeting of shareholders in June. As many of you know, I've been intimately involved with the leadership team in developing and executing Sanara's strategic vision, since the inception of Sanara MedTech. And I'm looking forward to working with the Sanara's leadership team now on a daily basis to continue that execution.